ASX:SVA

Stock Analysis Report

Executive Summary

Simavita Limited develops wearable and disposable sensors for the diaper industry primarily in Australia, North America, and Europe.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Simavita's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SVA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

SVA

4.1%

AU Medical Equipment

2.8%

AU Market


1 Year Return

n/a

SVA

15.0%

AU Medical Equipment

-16.2%

AU Market

Return vs Industry: Insufficient data to determine how SVA performed against the Australian Medical Equipment industry.

Return vs Market: Insufficient data to determine how SVA performed against the Australian Market.


Shareholder returns

SVAIndustryMarket
7 Day0%4.1%2.8%
30 Day13.3%-7.2%-15.2%
90 Day-45.2%-14.0%-23.4%
1 Yearn/a17.1%15.0%-12.4%-16.2%
3 Year-71.6%-72.6%35.6%29.1%-0.2%-13.9%
5 Year-96.5%-96.6%77.2%66.1%11.5%-13.6%

Price Volatility Vs. Market

How volatile is Simavita's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Simavita undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Simavita is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Simavita has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of SVA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Simavita regulatory filings.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Simavita forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

39.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Simavita has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Simavita performed over the past 5 years?

20.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SVA is currently unprofitable.

Growing Profit Margin: SVA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SVA is unprofitable, but has reduced losses over the past 5 years at a rate of 20.7% per year.

Accelerating Growth: Unable to compare SVA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SVA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.7%).


Return on Equity

High ROE: SVA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Simavita's financial position?


Financial Position Analysis

Short Term Liabilities: SVA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: SVA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: SVA has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: SVA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SVA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SVA has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.4% each year.


Next Steps

Dividend

What is Simavita's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SVA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SVA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SVA's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Simavita has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Spooner
Executive Chairman4yrsAU$300.00kno data
Peter Curran
Chief Technology Officer5.92yrsAU$341.23kno data
Peta Jurd
Chief Commercial Officer & Company Secretary4.25yrsAU$345.46kno data
Graham Blackett
Company Secretary0.83yrno datano data

2.5yrs

Average Tenure

Experienced Management: SVA's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Spooner
Executive Chairman4yrsAU$300.00kno data
Gary Pace
Independent Non-Executive Director4yrsAU$100.00kno data
Alan Fisher
Independent Non-Executive Director0.75yrno datano data
Susan Macri
Member of Clinical & Scientific Advisoryno datano datano data
Damien Haakman
Non-Executive Director1.33yrsAU$27.82k0.00098% A$70.3
Joseph Ouslander
Member of Clinical & Scientific Advisoryno datano datano data
David Fonda
Member of Clinical & Scientific Advisoryno datano datano data
Alan Cottenden
Member of Clinical & Scientific Advisoryno datano datano data
John McBain
Director0.42yrno data2.03% A$146.0k

1.3yrs

Average Tenure

65yo

Average Age

Experienced Board: SVA's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.5%.


Top Shareholders

Company Information

Simavita Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Simavita Limited
  • Ticker: SVA
  • Exchange: ASX
  • Founded: 1968
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$7.175m
  • Shares outstanding: 512.53m
  • Website: https://simavita.com

Number of Employees


Location

  • Simavita Limited
  • 54 Miller Street
  • Suite 2.02
  • North Sydney
  • New South Wales
  • 2060
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SVAASX (Australian Securities Exchange)YesCDI NPV 1:1AUAUDFeb 2014
SVACHIA (Chi-X Australia)YesCDI NPV 1:1AUAUDFeb 2014

Biography

Simavita Limited develops wearable and disposable sensors for the diaper industry primarily in Australia, North America, and Europe. It offers Smartz, a disruptive platform technology that provides real time alerts giving peace of mind to parents and carers of infants and adults; and assessPLUS, a solution for the assessment and management of incontinence. The company was incorporated in 1968 and is headquartered in North Sydney, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 12:34
End of Day Share Price2020/04/07 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.